New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 2, 2013
06:46 EDTBLUEBluebird Bio announces first patient transplanted in Phase 1/2 HGB-205
Bluebird Bio announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
News For BLUE From The Last 14 Days
Check below for free stories on BLUE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BLUE

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use